10 Best Performing Weight Loss Companies And Their Programs

Page 5 of 11

7. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

1-Year Returns: -4.64%

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a number of treatments in its pipeline, with its weight loss treatment Belviq, which was approved by the FDA back in 2012, being the first to reach market. However, sales of the drug were sluggish, leading to the ouster of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s CEO and co-founder last March, and prompting Arena to sell the development and marketing rights for the drug to Eisai in January, landing it a $23 million payment and sparing it further costs associated with expanding the market for the drug. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is still poised to benefit from Belviq’s potential success through royalty payments that could reach as much as 18.5% of the drug’s global sales. JMP Securities’ Jason Butler viewed the deal as being favorable for Arena Pharmaceuticals.

Billion Photos/Shutterstock.com

Billion Photos/Shutterstock.com

Follow Arena Pharmaceuticals Inc (NASDAQ:ARNA)

Page 5 of 11